Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents

Catheterization and Cardiovascular Interventions

Volumn 79, Issue 4, 2012, Pages 575-582

  Morrison, T Ben ^a   Horst, Brian M ^b   Brown, Michael J ^c   Bell, Malcolm R ^c   Daniels, Paul R ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

clopidogrel; eptifibatide; thrombosis

Indexed keywords

CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; FEMALE; HEART SURGERY; HUMAN; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; STENT THROMBOSIS; THERAPY EFFECT;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIAC SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINNESOTA; PATIENT SELECTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863421560     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23172     Document Type: Article

References (36)

1. American Heart Association. Heart Disease and Stroke Statistics: 2009 Update At-a-Glance. Dallas, Texas: American Heart Association; 2009.
2. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 2009; 74: E25-E68.
3. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H,. Coronary artery stenting and non-cardiac surgery-A prospective outcome study. Br J Anaesth 2006; 96: 686-693. (Pubitemid 43786682)
4. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE,. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35: 1288-1294. (Pubitemid 30206904)
5. Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, Lindsay J,. Major noncardiac surgery following coronary stenting: When is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141-145. (Pubitemid 39313402)
6. Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, Melby S, Berger PB,. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234-240. (Pubitemid 36851411)
7. Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun M, Feringa HH, Hoeks SE, Poldermans D,. Noncardiac surgery after coronary stenting: Early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49: 122-124. (Pubitemid 46026891)
8. Nuttall GA, Brown MJ, Stombaugh JW, Michon PB, Hathaway MF, Lindeen KC, Hanson AC, Schroeder DR, Oliver WC, Holmes DR, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 2008; 109: 588-595.
9. Auer J, Berent R, Weber T, Eber B,. Risk of noncardiac surgery in the months following placement of a drug-eluting coronary stent. J Am Coll Cardiol 2004; 43: 713; author reply 714- 715. (Pubitemid 38229551)
10. Chung D, Krysiak P,. Post-mediastinoscopy mortality due to drug-eluting stent thrombosis. Eur J Cardiothorac Surg 2007; 31: 1149-1150. (Pubitemid 46719980)
11. Nasser M, Kapeliovich M, Markiewicz W,. Late thrombosis of sirolimus-eluting stents following noncardiac surgery. Catheter Cardiovasc Interv 2005; 65: 516-519. (Pubitemid 41060756)
12. Rabbitts JA, Nuttall GA, Brown MJ, Hanson AC, Oliver WC, Holmes DR, Rihal CS,. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 2008; 109: 596-604.
13. Kim HL, Park KW, Kwak JJ, Kim YS, Sir JJ, Lee SJ, Lee HY, Chang HJ, Kang HJ, Cho YS, et al. Stent-related cardiac events after non-cardiac surgery: Drug-eluting stent vs. bare metal stent. Int J Cardiol 2008; 123: 353-354.
14. Burzotta F, Parma A, Pristipino C, Manzoli A, Belloni F, Sardella G, Rigattieri S, Danesi A, Mazzarotto P, Summaria F, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: The OPTIMIST study. Eur Heart J 2008; 29: 3011-3021.
15. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130. (Pubitemid 40617065)
16. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947-953. (Pubitemid 40342824)
17. Abualsaud AO, Eisenberg MJ,. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv 2010; 3: 131-142.
18. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50: 1707-1732.
19. Brilakis ES, Banerjee S, Berger PB,. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49: 2145-2150. (Pubitemid 46824115)
20. Newsome LT, Weller RS, Gerancher JC, Kutcher MA, Royster RL,. Coronary artery stents. II. Perioperative considerations and management. Anesth Analg 2008; 107: 570-590.
21. Rabbat MG, Bavry AA, Bhatt DL, Ellis SG,. Understanding and minimizing late thrombosis of drug-eluting stents. Cleve Clin J Med 2007; 74: 129-136.
22. Bigalke B, Seizer P, Geisler T, Lindemann S, Gawaz M, May AE,. Perioperative antiplatelet therapy in patients at risk for coronary stent thrombosis undergoing noncardiac surgery. Clin Res Cardiol 2009; 98: 335-339.
23. Savonitto S, D'Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, Klugmann S, De Servi S,. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: A phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104: 285-291.
24. Broad L, Lee T, Conroy M, Bolsin S, Orford N, Black A, Birdsey G,. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 2007; 98: 19-22. (Pubitemid 44896746)
25. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W,. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-204.
26. Thygesen K, Alpert JS, White HD,. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-2195. (Pubitemid 350123680)
27. Laskey WK, Yancy CW, Maisel WH,. Thrombosis in coronary drug-eluting stents: Report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health. December 7-8, 2006. Circulation 2007; 115: 2352-2357. (Pubitemid 46685904)
28. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436-443.
29. Herman CR, Buth KJ, Kent BA, Hirsch GM,. Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg 2010; 89: 397-402.
30. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
31. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
32. U.S. Food and Drug Administration. EFFIENT Label Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022307s002lbl.pdf. Accessed 17 February 2011.
33. European Medicines Agency. Brilique: EPAR-Product Information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001241/WC500100494.pdf. Accessed 10 February 2011.
34. Paikin JS, Eikelboom JW, Cairns JA, Hirsh J,. New antithrombotic agents-Insights from clinical trials. Nat Rev Cardiol 2010; 7: 498-509.
35. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K,. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001; 52: 333-336. (Pubitemid 33796233)
36. Burger W, Chemnitius JM, Kneissl GD, Rucker G., Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-Review and meta-analysis. J Intern Med 2005; 257: 399-414. (Pubitemid 40604544)